However, the multifaceted roles played by SHMT2 in the regulation of numerous biological pathways do not support the possibility of utilizing the association of KEN‐SHMT2 as a therapeutic approach to AD, and the reduced amyloidogenesis is just one of the multiple consequences mediated by SHMT2. This evidence concerns the gene SHMT2 and Alzheimer disease.